Phase 2 Nab®-Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC)


About this study

This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Non- metastasis, unresectable, adenocarcinoma pancreatic cancer patients
  • No prior anticancer therapy for pancreatic cancer
  • ≥ 18 years of age with a performance status of 0 or 1
  • Adequate complete blood counts, hepatic function, and renal function
  • Signed informed Consent

Exclusion Criteria:

  • Active bacterial, viral, or fungal infection
  • Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressive
  • Subjects with sensory neuropathy, ascites, or plastic biliary stent.
  • Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders (including but not limited to connective tissue disorders, lung disease, and cardiac or seizure disorders)
  • Women who are pregnant or breast feeding

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Ramesh Ramanathan, M.D.

Closed for enrollment

Contact information:

Research Information Center


More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions